|
1
|
Richeldi L, Collard HR and Jones MG:
Idiopathic pulmonary fibrosis. Lancet. 389:1941–1952.
2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Kekevian A, Gershwin ME and Chang C:
Diagnosis and classification of idiopathic pulmonary fibrosis.
Autoimmun Rev. 13:508–512. 2014.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Raghu G, Chen SY, Hou Q, Yeh WS and
Collard HR: Incidence and prevalence of idiopathic pulmonary
fibrosis in US adults 18-64 years old. Eur Respir J. 48:179–186.
2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Raghu G, Rochwerg B, Zhang Y, Garcia CA,
Azuma A, Behr J, Brozek JL, Collard HR, Cunningham W, Homma S, et
al: An Official ATS/ERS/JRS/ALAT clinical practice guideline:
Treatment of idiopathic pulmonary fibrosis. an update of the 2011
clinical practice guideline. Am J Respir Crit Care Med. 192:e3–19.
2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Adamali HI and Maher TM: Current and novel
drug therapies for idiopathic pulmonary fibrosis. Drug Des Devel
Ther. 6:261–272. 2012.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Bonella F, Stowasser S and Wollin L:
Idiopathic pulmonary fibrosis: Current treatment options and
critical appraisal of nintedanib. Drug Des Devel Ther. 9:6407–6419.
2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Shenderov K, Collins SL, Powell JD and
Horton MR: Immune dysregulation as a driver of idiopathic pulmonary
fibrosis. J Clin Invest. 131(e143226)2021.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Sgalla G, Iovene B, Calvello M, Ori M,
Varone F and Richeldi L: Idiopathic pulmonary fibrosis:
Pathogenesis and management. Respir Res. 19(32)2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
American Thoracic Society. Idiopathic
pulmonary fibrosis. Diagnosis and treatment. International
consensus statement. American Thoracic Society (ATS), and the
European Respiratory Society (ERS). Am J Respir Crit Care Med.
161:646–664. 2000.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Spagnolo P, Tzouvelekis A and Bonella F:
The management of patients with idiopathic pulmonary fibrosis.
Front Med (Lausanne). 5(148)2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Kelly M, Kolb M, Bonniaud P and Gauldie J:
Re-evaluation of fibrogenic cytokines in lung fibrosis. Curr Pharm
Des. 9:39–49. 2003.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Hernandez DM, Kang JH, Choudhury M,
Andrianifahanana M, Yin X, Limper AH and Leof EB: IPF pathogenesis
is dependent upon TGFβ induction of IGF-1. FASEB J. 34:5363–5388.
2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Aston C, Jagirdar J, Lee TC, Hur T, Hintz
RL and Rom WN: Enhanced insulin-like growth factor molecules in
idiopathic pulmonary fibrosis. Am J Respir Crit Care Med.
151:1597–1603. 1995.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Alzahrani AS: PI3K/Akt/mTOR inhibitors in
cancer: At the bench and bedside. Semin Cancer Biol. 59:125–132.
2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Ma H, Liu S, Li S and Xia Y: Targeting
growth factor and cytokine pathways to treat idiopathic pulmonary
fibrosis. Front Pharmacol. 13(918771)2022.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Tsai HJ and Tseng CP: The adaptor protein
Disabled-2: New insights into platelet biology and integrin
signaling. Thromb J. 14 (Suppl 1)(S28)2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Cheong SM, Choi H, Hong BS, Gho YS and Han
JK: Dab2 is pivotal for endothelial cell migration by mediating
VEGF expression in cancer cells. Exp Cell Res. 318:550–557.
2012.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Hocevar BA, Smine A, Xu XX and Howe PH:
The adaptor molecule Disabled-2 links the transforming growth
factor beta receptors to the Smad pathway. EMBO J. 20:2789–2801.
2001.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Mei X, Zhao H, Huang Y, Tang Y, Shi X, Pu
W, Jiang S, Ma Y, Zhang Y, Bai L, et al: Involvement of Disabled-2
on skin fibrosis in systemic sclerosis. J Dermatol Sci. 99:44–52.
2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Wang BW, Fang WJ and Shyu KG: MicroRNA-145
regulates disabled-2 and Wnt3a expression in cardiomyocytes under
hyperglycaemia. Eur J Clin Invest: 48, 2018 doi:
10.1111/eci.12867.
|
|
21
|
Lin CM, Fang WJ, Wang BW, Pan CM, Chua SK,
Hou SW and Shyu KG: (-)-Epigallocatechin Gallate Promotes MicroRNA
145 Expression against Myocardial Hypoxic Injury through
Dab2/Wnt3a/β-catenin. Am J Chin Med. 48:341–356. 2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Ma W, Kang Y, Ning L, Tan J, Wang H and
Ying Y: Identification of microRNAs involved in gefitinib
resistance of non-small-cell lung cancer through the insulin-like
growth factor receptor 1 signaling pathway. Exp Ther Med.
14:2853–2862. 2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Barratt SL, Creamer A, Hayton C and
Chaudhuri N: Idiopathic Pulmonary Fibrosis (IPF): An Overview. J
Clin Med. 7(201)2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Fu L, Rab A, Tang LP, Rowe SM, Bebok Z and
Collawn JF: Dab2 is a key regulator of endocytosis and
post-endocytic trafficking of the cystic fibrosis transmembrane
conductance regulator. Biochem J. 441:633–643. 2012.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Tseng CP, Ely BD, Li Y, Pong RC and Hsieh
JT: Regulation of rat DOC-2 gene during castration-induced rat
ventral prostate degeneration and its growth inhibitory function in
human prostatic carcinoma cells. Endocrinology. 139:3542–3553.
1998.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Sheng Z, Sun W, Smith E, Cohen C, Sheng Z
and Xu XX: Restoration of positioning control following Disabled-2
expression in ovarian and breast tumor cells. Oncogene.
19:4847–4854. 2000.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Finkielstein CV and Capelluto DG:
Disabled-2: A modular scaffold protein with multifaceted functions
in signaling. Bioessays. 38 (Suppl 1):S45–S55. 2016.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Hocevar BA, Mou F, Rennolds JL, Morris SM,
Cooper JA and Howe PH: Regulation of the Wnt signaling pathway by
disabled-2 (Dab2). EMBO J. 22:3084–3094. 2003.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Dong R, Yu J, Yu F, Yang S, Qian Q and Zha
Y: IGF-1/IGF-1R blockade ameliorates diabetic kidney disease
through normalizing Snail1 expression in a mouse model. Am J
Physiol Endocrinol Metab. 317:E686–E698. 2019.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Pineiro-Hermida S, Lopez IP, Alfaro-Arnedo
E, Torrens R, Iñiguez M, Alvarez-Erviti L, Ruíz-Martínez C and
Pichel JG: IGF1R deficiency attenuates acute inflammatory response
in a bleomycin-induced lung injury mouse model. Sci Rep.
7(4290)2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Chung EJ, Kwon S, Reedy JL, White AO, Song
JS, Hwang I, Chung JY, Ylaya K, Hewitt SM and Citrin DE: IGF-1
Receptor signaling regulates type II pneumocyte senescence and
resulting macrophage polarization in lung fibrosis. Int J Radiat
Oncol Biol Phys. 110:526–538. 2021.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Koral K and Erkan E: PKB/Akt partners with
Dab2 in albumin endocytosis. Am J Physiol Renal Physiol.
302:F1013–1024. 2012.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Goldbraikh D, Neufeld D, Eid-Mutlak Y,
Lasry I, Gilda JE, Parnis A and Cohen S: USP1 deubiquitinates Akt
to inhibit PI3K-Akt-FoxO signaling in muscle during prolonged
starvation. EMBO Rep. 21(e48791)2020.PubMed/NCBI View Article : Google Scholar
|
